Prostate cancer treatments can affect urinary control, erections and orgasm, bowel function, libido, testosterone-dependent body systems and long-term quality of life—and the pattern depends strongly on the treatment used. Radical prostatectomy most often causes an immediate urinary-leakage and erectile-function burden. External-beam radiation and brachytherapy more often cause urinary irritation and bowel effects, with sexual function declining more gradually. Androgen deprivation therapy can reduce libido and erections while also affecting hot flashes, muscle, fat, bone, metabolism and energy. These trade-offs should be considered alongside cancer-control benefit rather than treated as secondary issues after treatment has already begun.
There is no single “prostate cancer treatment side-effect profile.” Surgery, radiation and androgen deprivation injure or alter different structures and therefore produce different timelines. Surgery has the strongest immediate effect on continence and erections; radiation more often causes irritative urinary and bowel symptoms and can produce delayed sexual decline; brachytherapy can cause pronounced urinary irritation early; androgen deprivation suppresses sexual desire and can affect bone, muscle, metabolism and cardiovascular health. Some effects improve over months, some remain stable, and some appear or worsen years later. Baseline function, age, treatment intensity and rehabilitation strongly influence the final outcome.
01How Do Side Effects Differ Between Surgery, Radiation and Hormone Therapy?
The treatment mechanism predicts the main adverse-effect pattern
Side effects are not random.
They usually follow the anatomy or physiology altered by treatment.
For example:
- radical prostatectomy removes the prostate and reconstructs the urinary tract near the external urinary sphincter and erectile neurovascular bundles;
- external-beam radiation delivers dose through or near the prostate, bladder neck, urethra and rectum;
- brachytherapy places high radiation dose directly around the prostate and prostatic urethra;
- and androgen deprivation lowers testosterone throughout the entire body.
What is the typical radical-prostatectomy side-effect profile?
The main functional risks are:
- stress urinary incontinence;
- erectile dysfunction;
- loss of ejaculation and natural fertility;
- orgasmic changes;
- urine leakage during sexual activity in some patients;
- and surgical complications such as stricture, bleeding, lymphocele or hernia.
The urinary and erectile effects are typically most obvious immediately after surgery and then recover to different degrees over months or years.
What is the typical external-radiation side-effect profile?
External-beam radiation more often produces:
- urinary frequency and urgency;
- burning with urination;
- nocturia;
- weaker stream;
- bowel frequency, urgency or rectal irritation;
- fatigue during treatment;
- and erectile dysfunction that can develop gradually.
Late complications can include:
- radiation cystitis;
- hematuria;
- urethral stricture;
- radiation proctitis;
- rectal bleeding;
- and a small long-term increase in secondary pelvic malignancies.
What is different about brachytherapy?
Brachytherapy concentrates radiation inside the prostate.
Its early functional burden is therefore often dominated by:
- frequency;
- urgency;
- weak stream;
- burning;
- and temporary urinary retention.
Current EAU guidance specifically advises patients that brachytherapy can worsen irritative urinary symptoms during the first year, while the difference is generally less apparent by five years.
What is different about androgen deprivation therapy?
Androgen deprivation has no surgical wound and no local pelvic radiation injury.
Its adverse effects instead result from testosterone suppression:
- loss of libido;
- erectile dysfunction;
- hot flashes;
- fatigue;
- loss of muscle;
- increase in body fat;
- bone-density loss;
- metabolic changes;
- and possible cardiovascular consequences.
Can treatments be combined?
Yes—and combination treatment can combine toxicities.
Examples include:
- radiation plus androgen deprivation;
- external-beam radiation plus brachytherapy boost;
- salvage radiation after prostatectomy;
- and advanced-disease systemic combinations.
A combined treatment can improve cancer control in the right risk group while increasing urinary, sexual, bowel or systemic burden.
What did the long-term ProtecT trial show?
ProtecT randomized 1,643 men with localized prostate cancer to active monitoring, prostatectomy or radiotherapy with short-course androgen deprivation.
From years 7 through 12:
- urinary pad use occurred in approximately 18–24% after prostatectomy;
- compared with 3–8% after radiotherapy;
- erections sufficient for intercourse at year 7 were reported by 18% after prostatectomy and 27% after radiotherapy;
- by year 12, potency had declined substantially in all groups;
- fecal leakage affected 12% after radiotherapy versus 6% after prostatectomy or active monitoring at year 12.
ProtecT remains valuable because it directly compares long-term patient-reported outcomes, but treatment techniques have evolved since participants were originally treated between 2001 and 2009. Modern robotic surgery, IMRT, image guidance and contemporary rehabilitation can change absolute rates.
Do not compare treatment side effects using one percentage from one study. Definitions, baseline function, age, surgical technique, radiation technology, ADT exposure and follow-up duration can all change the reported rate.
02What Urinary Side Effects Can Prostate Cancer Treatment Cause?
Urinary incontinence and urinary irritation are different outcomes
The term “urinary side effects” can describe several distinct problems:
- stress incontinence — leakage with coughing, lifting, walking or exertion;
- urgency incontinence — leakage associated with a sudden urge;
- frequency and nocturia — needing to urinate often or repeatedly overnight;
- dysuria — burning or discomfort;
- obstruction — weak stream or difficulty emptying;
- retention — inability to empty the bladder;
- stricture — scar-related narrowing of the urethra or bladder-neck connection.
Why does surgery cause leakage?
Radical prostatectomy removes the prostate from between the bladder and urinary sphincter and then reconnects the bladder to the remaining urethra.
Continence after surgery depends on:
- sphincter integrity;
- functional urethral length;
- pelvic-floor support;
- bladder function;
- nerve preservation;
- and surgical reconstruction.
Leakage is expected early after catheter removal and usually improves substantially over the following months.
How common is persistent incontinence after prostatectomy?
Rates vary because definitions differ.
EAU cites a prospective multicentre comparison in which urinary incontinence at 12 months was:
- 21.3% after robot-assisted radical prostatectomy;
- 20.2% after open retropubic prostatectomy.
Long-term ProtecT data found pad use in approximately 18–24% of the prostatectomy group during years 7–12.
These studies use different populations and definitions and should not be merged into one expected personal risk.
Can pelvic-floor exercises help?
Yes, particularly in accelerating recovery.
The AUA/GURS/SUFU incontinence guideline recommends that clinicians:
- may offer pelvic-floor muscle training before radical prostatectomy;
- and should offer pelvic-floor muscle exercises or training in the immediate postoperative period.
EAU reviews suggest pelvic-floor training can shorten time to continence recovery, although the best program, supervision level and adjuncts remain uncertain.
When should persistent post-prostatectomy incontinence be treated surgically?
If bothersome stress incontinence is not improving despite conservative treatment, AUA guidance allows surgical treatment to be considered as early as about six months.
If bothersome leakage persists at one year despite conservative therapy, surgical treatment should be offered.
Options can include:
- male sling;
- artificial urinary sphincter;
- and other selected continence procedures.
Why does radiation cause a different urinary pattern?
Radiation usually leaves the sphincter and prostate in place.
The more typical acute pattern is inflammation of:
- prostate;
- prostatic urethra;
- bladder neck;
- and nearby bladder tissue.
This causes:
- urgency;
- frequency;
- nocturia;
- burning;
- and weaker urinary stream.
Why can brachytherapy cause retention?
Brachytherapy adds high local radiation dose directly through the prostate and around the urethra.
Post-implant swelling plus urethral inflammation can narrow the urinary channel temporarily.
This is why baseline urinary function is central to brachytherapy selection.
What urinary effects can appear years after radiation?
Delayed problems can include:
- urethral stricture;
- hematuria from radiation cystitis;
- persistent urgency;
- and less commonly severe incontinence.
Urinary recovery should be defined by the actual symptom. A patient with stress leakage after surgery needs a different evaluation from a patient with urgency after radiation or obstruction after brachytherapy.
03How Do Prostate Cancer Treatments Affect Erections, Libido, Orgasm and Ejaculation?
“Sexual side effects” include more than erectile dysfunction
Treatment can affect:
- sexual desire;
- erection rigidity;
- ability to maintain an erection;
- orgasm sensation;
- ejaculation;
- fertility;
- penile length or perceived length;
- and sexual confidence or relationship intimacy.
Why can erections disappear immediately after prostatectomy?
The neurovascular bundles responsible for erectile signaling lie directly against the prostate capsule.
Even when nerves are preserved anatomically, temporary nerve dysfunction can result from:
- traction;
- thermal injury;
- inflammation;
- local vascular change;
- and tissue manipulation.
If one or both nerve bundles must be removed for cancer control, erectile recovery becomes less likely.
What do contemporary outcome data show after surgery?
EAU cites a multicentre prospective study in which erectile dysfunction at 12 months occurred in:
- 70.4% after robot-assisted radical prostatectomy;
- 74.7% after open radical prostatectomy.
The same EAU review notes similar functional outcomes between approaches at 24 months.
The surgical platform therefore does not guarantee sexual recovery.
What predicts erectile recovery after prostatectomy?
Important variables include:
- age;
- erectile function before treatment;
- diabetes and cardiovascular health;
- tumor location;
- bilateral versus unilateral nerve sparing;
- quality of nerve preservation;
- and time since surgery.
Can erectile dysfunction be treated after surgery?
Yes.
Options can include:
- PDE5 inhibitors such as sildenafil or tadalafil;
- vacuum erection devices;
- intracavernosal injections;
- intraurethral medication in selected patients;
- and penile prosthesis when less invasive treatments are ineffective or unsuitable.
The deeper prostate-cancer-specific rehabilitation pathway is covered in the next guide: Erectile Dysfunction After Prostate Cancer Treatment.
For erectile dysfunction beyond the prostate-cancer setting, see the broader Erectile Dysfunction topic.
Why does radiation cause a more gradual erectile decline?
Radiation usually does not cut the erectile neurovascular bundles.
Instead, erectile function can decline over months or years through:
- vascular injury;
- fibrosis;
- dose to neurovascular and penile structures;
- aging;
- and the effects of concurrent androgen deprivation.
What does androgen deprivation do differently?
Androgen deprivation affects both:
- sexual desire;
- and erectile physiology.
EAU reports cessation of sexual activity in up to 93% of men receiving androgen deprivation in some studies.
This matters because an erection medication cannot fully correct the loss of libido caused by severe testosterone suppression.
What happens to ejaculation after prostatectomy?
Ejaculation is permanently lost because the prostate and seminal vesicles are removed and the ejaculatory pathway is disconnected.
Orgasm can still occur, but it is dry.
Can orgasm change even if erection recovery is good?
Yes.
Possible changes include:
- weaker or different orgasm sensation;
- painful orgasm;
- climacturia—urine leakage at orgasm;
- arousal incontinence;
- and changes in penile length or sensation.
Erectile function and sexual function are not interchangeable. A patient can recover an erection but still have low libido, altered orgasm, dry ejaculation or climacturia. Rehabilitation should target the symptom that is actually limiting sexual quality of life.
04What Bowel Side Effects Can Radiation Cause?
The rectum lies directly behind the prostate
This anatomy makes the rectum the main bowel organ at risk during prostate radiation.
Modern IMRT, VMAT, image guidance and selected rectal spacers reduce exposure compared with older techniques, but they do not reduce dose to zero.
What bowel symptoms can happen during radiation?
Acute effects can include:
- increased stool frequency;
- looser stools;
- rectal urgency;
- tenesmus—the sensation of needing to pass stool;
- mucus;
- discomfort;
- and minor rectal bleeding.
These symptoms often improve in the weeks or months after treatment.
What bowel effects can appear later?
Late radiation effects can include:
- chronic radiation proctitis;
- intermittent rectal bleeding;
- urgency;
- stool leakage;
- and less commonly ulceration, stricture or fistula.
What did ProtecT show about long-term bowel function?
By year 12, fecal leakage at least weekly was reported by:
- 12% of the radiotherapy group;
- 6% of the prostatectomy group;
- 6% of the active-monitoring group.
The earlier excess of blood in the stool after radiotherapy had largely resolved by years 7–12.
Again, ProtecT used radiation techniques from an earlier treatment era, so the absolute rate should not be interpreted as a direct prediction for a patient receiving modern image-guided IMRT or MRI-guided treatment.
Does surgery cause bowel dysfunction?
Bowel dysfunction is not a dominant chronic side effect of uncomplicated radical prostatectomy.
However, the rectum is immediately behind the prostate, so rectal injury can occur rarely during surgery and can become serious if it causes:
- infection;
- fistula;
- or need for additional surgery.
Can salvage treatment increase bowel risk?
Yes.
Treatment delivered to previously treated tissue can carry a higher complication risk.
Examples include:
- salvage surgery after radiation;
- re-irradiation;
- or some focal salvage procedures.
These decisions require specialist assessment because tissue healing and vascularity may already be altered.
Bowel toxicity is primarily a radiation-domain effect, but severity depends on rectal dose and technology. A patient treated with current image-guided IMRT should not assume that historical bowel-toxicity percentages exactly represent modern individual risk.
05What Hormonal and Whole-Body Side Effects Can Treatment Cause, and What Helps Recovery?
Androgen deprivation affects tissues throughout the body
The previous guide explains Androgen Deprivation Therapy for Prostate Cancer in detail.
Its adverse effects can include:
- loss of libido;
- erectile dysfunction;
- hot flashes;
- fatigue;
- loss of lean muscle;
- gain in body fat;
- reduced bone mineral density;
- fracture risk;
- insulin resistance;
- changes in cholesterol and triglycerides;
- weight gain;
- mood changes;
- and anemia.
How common are hot flashes?
EAU estimates hot flashes affect approximately 44–80% of men receiving androgen deprivation.
They often begin within the first several months and can persist throughout treatment.
Why is bone health important?
Testosterone supports normal bone remodeling.
Long-term androgen deprivation accelerates bone mineral-density loss and increases fracture risk.
Current EAU guidance recommends baseline DEXA scanning for men starting long-term treatment and appropriate antiresorptive therapy for patients with osteoporosis or sufficiently high fracture risk.
Why is exercise part of treatment rather than generic wellness advice?
EAU strongly recommends supervised combined aerobic and resistance exercise for men receiving androgen deprivation.
Exercise can help counter:
- loss of muscle;
- fat gain;
- fatigue;
- loss of cardiovascular fitness;
- and reduced functional independence.
EAU meta-analytic evidence also shows supervised exercise improves fatigue, cancer-specific quality of life and muscular strength.
What does multidisciplinary rehabilitation address?
Current EAU guidance recommends specialist nurse-led multidisciplinary rehabilitation after radical treatment based on the patient’s individual goals.
A program can address:
- urinary incontinence;
- sexual dysfunction;
- bowel symptoms;
- depression and anxiety;
- fear of recurrence;
- relationship concerns;
- social support;
- exercise and physical function;
- and positive lifestyle change.
Do side effects always disappear when treatment ends?
No.
Three different patterns matter:
- reversible effects — such as many acute urinary or bowel symptoms;
- partially recoverable effects — such as continence or erections after surgery;
- potentially permanent or cumulative effects — such as dry ejaculation after prostatectomy, some radiation injury, or bone loss after prolonged androgen deprivation.
Testosterone recovery after temporary androgen deprivation can also take months or years and may remain incomplete in older patients or after long treatment courses.
When should a symptom be reassessed rather than accepted as a treatment side effect?
A treatment history can explain many symptoms, but it should not become a reason to ignore new disease.
Examples that deserve reassessment include:
- new gross hematuria;
- persistent rectal bleeding;
- new urinary retention;
- new severe pelvic or bone pain;
- new neurologic symptoms;
- progressive leg swelling;
- unexplained weight loss;
- or symptoms occurring alongside a concerning PSA change.
These findings can represent treatable complications, recurrence or an unrelated condition rather than an expected survivorship effect.
Survivorship starts at treatment selection. Baseline urinary, sexual, bowel, bone, metabolic and cardiovascular function should be documented before therapy because it determines both risk and what “recovery” realistically means afterward.
→Side-Effect Comparison by Treatment
| Treatment | Urinary | Sexual | Bowel | Hormonal / systemic | Typical timing |
|---|---|---|---|---|---|
| Radical prostatectomy | Stress leakage early; persistent incontinence in a minority; bladder-neck/urethral stricture possible. | Immediate ED common; ejaculation permanently lost; orgasm/climacturia can change. | Usually limited unless surgical rectal injury occurs. | No direct testosterone suppression. | Immediate functional hit → recovery over months; some deficits persist. |
| External-beam radiation | Frequency, urgency, dysuria, nocturia; late hematuria/stricture possible. | Gradual erectile decline; worsened when ADT is combined. | Urgency, loose stool, bleeding; delayed proctitis/leakage possible. | Only when systemic hormonal treatment is added. | Symptoms build during treatment; some late effects appear years later. |
| Brachytherapy | Strong early irritative/obstructive pattern; retention possible; late stricture risk. | Gradual erectile decline possible. | Usually modest but rectal symptoms can occur. | Only if ADT is added. | Urinary burden often greatest in first months and improves over time. |
| Androgen deprivation | Not usually the dominant toxicity. | Low libido and ED are very common. | Not a dominant class effect; individual drugs can affect GI function. | Hot flashes, fatigue, sarcopenia, fat gain, bone loss, metabolic and cardiovascular effects. | Begins within weeks/months; cumulative with longer treatment; recovery after stopping may be delayed. |
| Combined therapy | Can combine local treatment toxicity with systemic burden. | Often greater sexual impact than either modality alone. | Depends on radiation field and dose. | Depends on ADT duration and added systemic agents. | Multiple overlapping recovery clocks. |
Key Points
- Prostate cancer treatments have different adverse-effect profiles; there is no single universal “side effect rate.”
- Radical prostatectomy most strongly affects urinary continence and erectile function immediately after treatment.
- External-beam radiation more commonly causes urinary irritation and bowel symptoms, with erectile function declining more gradually.
- Brachytherapy can cause substantial temporary urinary frequency, urgency, weak flow and retention because the prostatic urethra receives high local dose.
- Androgen deprivation can reduce libido and erections while also affecting bone, muscle, fat, glucose, lipids, energy and cardiovascular risk.
- ProtecT found urinary pad use in 18–24% after prostatectomy versus 3–8% after radiotherapy during years 7–12.
- At year 7 in ProtecT, intercourse-sufficient erections were reported by 18% after prostatectomy versus 27% after radiotherapy.
- At year 12, fecal leakage affected 12% after radiotherapy versus 6% after prostatectomy or active monitoring.
- ProtecT used treatment techniques from an earlier era; its long-term pattern is highly informative, but exact percentages should not be treated as a modern individual prediction.
- EAU cites 12-month erectile dysfunction rates above 70% after both robotic and open radical prostatectomy in a prospective multicentre cohort.
- Urinary leakage after prostatectomy usually improves substantially during the first year but can remain bothersome and treatable.
- AUA guidance recommends immediate postoperative pelvic-floor muscle training and supports surgery for persistent bothersome stress incontinence when conservative recovery has plateaued.
- Sexual recovery should consider libido, erections, orgasm and ejaculation separately.
- Androgen deprivation can lead to cessation of sexual activity in a large proportion of patients because it suppresses desire as well as erectile function.
- EAU estimates hot flashes occur in approximately 44–80% of men receiving androgen deprivation.
- Long-term androgen deprivation requires bone-density and metabolic-risk monitoring.
- Supervised combined resistance and aerobic exercise is strongly recommended during androgen deprivation.
- Multidisciplinary rehabilitation after radical treatment can address continence, sexuality, bowel symptoms, depression, fear of recurrence and lifestyle recovery together.
- New bleeding, retention, severe pain or neurologic symptoms should be reassessed rather than automatically accepted as a routine treatment effect.
- Side-effect trade-offs should be discussed before treatment because baseline function strongly influences the probability and meaning of recovery.
Clinical bottom line: prostate cancer treatment side effects follow the biology and anatomy of the treatment. Surgery removes the prostate and alters the urinary and erectile structures around it, producing the strongest immediate continence and erectile burden. Radiation preserves the gland but exposes the urethra, bladder neck, rectum and nearby erectile tissues to radiation, producing a different pattern of irritation, bowel effects and gradual sexual decline. Brachytherapy concentrates that dose inside the prostate and therefore places particular pressure on urinary function. Androgen deprivation acts throughout the body, suppressing libido while affecting bone, muscle, fat, metabolism and energy. Many side effects improve, but some remain persistent or emerge later. The best treatment decision therefore considers cancer control and baseline urinary, sexual, bowel and systemic health at the same time, followed by active rehabilitation rather than passive observation of avoidable disability.
Medical disclaimer: This article provides general medical education about adverse effects of prostate cancer treatment. Individual risk depends on cancer stage, treatment type and intensity, baseline urinary and sexual function, bowel health, age, comorbidity, radiation dose and field, nerve-sparing feasibility, androgen-deprivation duration, medications and rehabilitation. New or severe symptoms should be assessed by the treating urology, radiation oncology or medical oncology team rather than assumed to be a routine treatment effect.
For the broader disease framework, return to the Prostate Cancer hub. The previous management guide covers Androgen Deprivation Therapy for Prostate Cancer. The next contextual guide focuses specifically on Erectile Dysfunction After Prostate Cancer Treatment. For erectile dysfunction outside the prostate-cancer treatment context, see the broader Erectile Dysfunction topic.
Evidence Sources
- European Association of Urology — Quality of Life Outcomes in Prostate Cancer: surgery, radiation, brachytherapy and androgen-deprivation effects; long-term ProtecT outcomes; rehabilitation, exercise, bone and survivorship recommendations.
- ProtecT Study Group — Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment: long-term urinary, sexual and bowel outcomes after prostatectomy, radiotherapy and active monitoring.
- National Cancer Institute — Prostate Cancer Treatment PDQ, Patient Version: adverse effects of surgery, radiation and hormone therapy.
- National Cancer Institute — Hormone Therapy for Prostate Cancer: sexual, skeletal, metabolic, cardiovascular and quality-of-life effects of androgen deprivation.
- AUA/GURS/SUFU — Incontinence after Prostate Treatment guideline, amended 2024: continence counseling, pelvic-floor therapy and timing of surgical treatment for persistent post-treatment stress incontinence.
- European Association of Urology — Male LUTS guideline: pelvic-floor muscle training and treatment options for post-prostatectomy urinary incontinence.
- European Association of Urology — Sexual and Reproductive Health guideline: erectile dysfunction management after radical prostatectomy, including PDE5 inhibitors, vacuum devices, injections and penile prosthesis.
